Catherine Wood's VRTX Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 25,665 shares of Vertex Pharmaceuticals Incorporated (VRTX) worth $10.05 M, representing 0.06% of the portfolio. First purchased in 2020-Q3, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in VRTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 902,852 shares. Largest reduction occurred in Q4 2021, reducing 780,960 shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Vertex Pharmaceuticals Incorporated (VRTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Vertex Pharmaceuticals Incorporated (VRTX) Trades by Catherine Wood
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2020 | +97,352 | New Buy | 97,352 | $272.12 |
| Q4 2020 | +718,842 | Add 738.39% | 816,194 | $236.34 |
| Q1 2021 | +902,852 | Add 110.62% | 1.72 M | $214.89 |
| Q2 2021 | +55,020 | Add 3.20% | 1.77 M | $201.63 |
| Q3 2021 | -64,315 | Reduce 3.63% | 1.71 M | $181.39 |
| Q4 2021 | -780,960 | Reduce 45.68% | 928,791 | $219.60 |
| Q1 2022 | -507,016 | Reduce 54.59% | 421,775 | $260.97 |
| Q2 2022 | -56,253 | Reduce 13.34% | 365,522 | $268.65 |
| Q3 2022 | -208,077 | Reduce 56.93% | 157,445 | $289.54 |
| Q4 2022 | -35,248 | Reduce 22.39% | 122,197 | $288.78 |
| Q1 2023 | -1,688 | Reduce 1.38% | 120,509 | $315.07 |
| Q2 2023 | -4,838 | Reduce 4.01% | 115,671 | $351.91 |
| Q3 2023 | -340 | Reduce 0.29% | 115,331 | $347.74 |
| Q4 2023 | +8,866 | Add 7.69% | 124,197 | $406.89 |
| Q1 2024 | -34,093 | Reduce 27.45% | 90,104 | $418.01 |
| Q2 2024 | -14,640 | Reduce 16.25% | 75,464 | $468.72 |
| Q3 2024 | -24,365 | Reduce 32.29% | 51,099 | $465.08 |
| Q4 2024 | -25,749 | Reduce 50.39% | 25,350 | $402.70 |
| Q1 2025 | +994 | Add 3.92% | 26,344 | $484.83 |
| Q2 2025 | -2,281 | Reduce 8.66% | 24,063 | $445.21 |
| Q3 2025 | +1,602 | Add 6.66% | 25,665 | $391.64 |
Catherine Wood's Vertex Pharmaceuticals Incorporated Investment FAQs
Catherine Wood first purchased Vertex Pharmaceuticals Incorporated (VRTX) in Q3 2020, acquiring 97,352 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Vertex Pharmaceuticals Incorporated (VRTX) for 21 quarters since Q3 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's largest addition to Vertex Pharmaceuticals Incorporated (VRTX) was in Q1 2021, adding 1,719,046 shares worth $369.41 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 25,665 shares of Vertex Pharmaceuticals Incorporated (VRTX), valued at approximately $10.05 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Vertex Pharmaceuticals Incorporated (VRTX) represents approximately 0.06% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's peak holding in Vertex Pharmaceuticals Incorporated (VRTX) was 1,774,066 shares, as reported at the end of Q2 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.